REBEKAH JAMES: Open Payments
NPI 1982854907 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 58 payments from 16 companies in 2025. Trend: 2023 $792 · 2024 $982 · 2025 $1,217
Food & beverage: $1,217
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $372 |
| Novo Nordisk Inc | 18 | $312 |
| Lilly USA, LLC | 5 | $88 |
| GlaxoSmithKline, LLC. | 5 | $77 |
| ABBVIE INC. | 4 | $65 |
| PFIZER INC. | 3 | $49 |
| Amgen Inc. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| GENZYME CORPORATION | 1 | $28 |
| Abbott Laboratories | 1 | $27 |
Products named: BREZTRI, Ozempic, Wegovy, MOUNJARO, Rybelsus, AIRSUPRA, TRELEGY ELLIPTA, FARXIGA.
Industry payments across FL — which companies pay providers there.
